Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Comirnaty (COVID-19 mRNA vaccine by Year
Comirnaty (COVID-19 mRNA vaccine — BioNTech collaboration) — U.S. reported YoY (%) (%)
Pfizer Comirnaty (COVID-19 mRNA vaccine: -17.0% in FY2025, unchanged from a year earlier.
Latest, FY2025
-17.0%
Period ended Dec 31, 2025
Change on a year earlier
0.0 pts
-17.0% in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Comirnaty | 4,367 | 5,353 | (18%) | (20%) | 1,663 | 2,004 | (17%) | 2,705 | 3,349 | (19%) | (21%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Comirnaty (COVID-19 mRNA vaccine — BioNTech collaboration) — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -17.0% | 0.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -17.0% | +38.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | -55.0% | -57.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | 2.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
Cite this data
StockData. (2026). Pfizer Comirnaty (COVID-19 mRNA vaccine (%), annual FY2022–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/comirnaty-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.